

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
01 July 2021 (01.07.2021)



(10) International Publication Number
WO 2021/129765 A1

(51) International Patent Classification:

C07K 16/28 (2006.01) A61K 39/395 (2006.01)

C12N 15/28 (2006.01)

(21) International Application Number:

PCT/CN2020/139143

(22) International Filing Date:

24 December 2020 (24.12.2020)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

PCT/CN2019/129095

27 December 2019 (27.12.2019) CN

(71) Applicant: NANJING LEGEND BIOTECH CO., LTD.

[CN/CN]; No. 6 Building of Nanjing Life Science Town,
No. 568 Longmian Avenue, Jiangning District, Nanjing,
Jiangsu 211100 (CN).

(72) Inventors: FAN, Xiaohu; 1067 Armitage Crescent SW,

Edmonton, Alberta T6W 0K3 (CA). ZHUANG, Qiuchuan;
Room 104, 36th Building, Yuecheng International Garden,
No. 9, Huashen Street, Yuhuatai District, Nanjing, Jiang-
su 210012 (CN). FANG, Xu; No. 6 Building of Nanjing
Life Science Town, No. 568 Longmian Avenue, Jiangning
District, Nanjing, Jiangsu 211100 (CN). ZHANG, Qing-
shan; No. 6 Building of Nanjing Life Science Town, No.
568 Longmian Avenue, Jiangning District, Nanjing, Jiang-
su 211100 (CN). XU, Manman; No. 6 Building of Nanjing
Life Science Town, No. 568 Longmian Avenue, Jiangning
District, Nanjing, Jiangsu 211100 (CN). FENG, Meng; No.
6 Building of Nanjing Life Science Town, No. 568 Long-
mian Avenue, Jiangning District, Nanjing, Jiangsu 211100
(CN).

(74) Agent: AFD CHINA INTELLECTUAL PROPERTY

LAW OFFICE; Tower B, 21st Fl., Suite 2108, 38 Xueqing
Road, Haidian, Beijing 100083 (CN).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

WO 2021/129765 A1

(54) Title: CLAUDIN18.2 BINDING MOIETIES AND USES THEREOF

(57) Abstract: Single domain antibodies that bind to Claudin18.2, and chimeric antigen receptors comprising same are provided. Further provided are engineered immune effector cells (such as T cells) comprising the chimeric antigen receptors. Pharmaceutical compositions, kits and methods of treating a disease or disorder are also provided.